Renalis develops FDA-cleared Prescription Digital Therapeutics for the treatment of pelvic conditions. Our lead product is CeCe® a mobile-enhanced digital therapeutic for first-line treatment of overactive bladder (OAB) in persons assigned female at birth. CeCe® delivers cost-effective, accessible, and engaging behavioral therapy to patients with OAB symptoms via their Apple or Android smartphone.